Literature DB >> 22592366

Family history of Alzheimer disease predicts hippocampal atrophy in healthy middle-aged adults.

O C Okonkwo1, G Xu, N M Dowling, B B Bendlin, A Larue, B P Hermann, R Koscik, E Jonaitis, H A Rowley, C M Carlsson, S Asthana, M A Sager, S C Johnson.   

Abstract

OBJECTIVE: To evaluate the longitudinal influence of family history (FH) of Alzheimer disease (AD) and apolipoprotein E ε4 allele (APOE4) on brain atrophy and cognitive decline over 4 years among asymptomatic middle-aged individuals.
METHODS: Participants were cognitively healthy adults with (FH+) (n = 60) and without (FH-) (n = 48) a FH of AD (mean age at baseline 54 years) enrolled in the Wisconsin Registry for Alzheimer's Prevention. They underwent APOE genotyping, cognitive testing, and an MRI scan at baseline and 4 years later. A covariate-adjusted voxel-based analysis interrogated gray matter (GM) modulated probability maps at the 4-year follow-up visit as a function of FH and APOE4. We also examined the influence of parent of origin on GM atrophy. Parallel analyses investigated the effects of FH and APOE4 on cognitive decline.
RESULTS: Neither FH nor APOE4 had an effect on regional GM or cognition at baseline. Longitudinally, a FH × APOE4 interaction was found in the right posterior hippocampus, which was driven by a significant difference between the FH+ and FH- subjects who were APOE4-. In addition, a significant FH main effect was observed in the left posterior hippocampus. No significant APOE4 main effects were detected. Persons with a maternal history of AD were just as likely as those with a paternal history of AD to experience posterior hippocampal atrophy. There was no longitudinal decline in cognition within the cohort.
CONCLUSION: Over a 4-year interval, asymptomatic middle-aged adults with FH of AD exhibit significant atrophy in the posterior hippocampi in the absence of measurable cognitive changes. This result provides further evidence that detectable disease-related neuroanatomic changes do occur early in the AD pathologic cascade.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22592366      PMCID: PMC3359586          DOI: 10.1212/WNL.0b013e3182583047

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  37 in total

Review 1.  Statistics notes: Analysing controlled trials with baseline and follow up measurements.

Authors:  A J Vickers; D G Altman
Journal:  BMJ       Date:  2001-11-10

2.  Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.

Authors:  Reisa A Sperling; Paul S Aisen; Laurel A Beckett; David A Bennett; Suzanne Craft; Anne M Fagan; Takeshi Iwatsubo; Clifford R Jack; Jeffrey Kaye; Thomas J Montine; Denise C Park; Eric M Reiman; Christopher C Rowe; Eric Siemers; Yaakov Stern; Kristine Yaffe; Maria C Carrillo; Bill Thies; Marcelle Morrison-Bogorad; Molly V Wagster; Creighton H Phelps
Journal:  Alzheimers Dement       Date:  2011-04-21       Impact factor: 21.566

3.  An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets.

Authors:  Joseph A Maldjian; Paul J Laurienti; Robert A Kraft; Jonathan H Burdette
Journal:  Neuroimage       Date:  2003-07       Impact factor: 6.556

4.  Estimating risk curves for first-degree relatives of patients with Alzheimer's disease: the REVEAL study.

Authors:  L Adrienne Cupples; Lindsay A Farrer; A Dessa Sadovnick; Norman Relkin; Peter Whitehouse; Robert C Green
Journal:  Genet Med       Date:  2004 Jul-Aug       Impact factor: 8.822

5.  Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design.

Authors:  L Frison; S J Pocock
Journal:  Stat Med       Date:  1992-09-30       Impact factor: 2.373

6.  Role of family history for Alzheimer biomarker abnormalities in the adult children study.

Authors:  Chengjie Xiong; Catherine M Roe; Virginia Buckles; Anne Fagan; David Holtzman; David Balota; Janet Duchek; Martha Storandt; Mark Mintun; Elizabeth Grant; Abraham Z Snyder; Denise Head; Tammie L S Benzinger; Joseph Mettenburg; John Csernansky; John C Morris
Journal:  Arch Neurol       Date:  2011-10

7.  A voxel-based morphometric study of ageing in 465 normal adult human brains.

Authors:  C D Good; I S Johnsrude; J Ashburner; R N Henson; K J Friston; R S Frackowiak
Journal:  Neuroimage       Date:  2001-07       Impact factor: 6.556

8.  Differential aging of the medial temporal lobe: a study of a five-year change.

Authors:  N Raz; K M Rodrigue; D Head; K M Kennedy; J D Acker
Journal:  Neurology       Date:  2004-02-10       Impact factor: 9.910

9.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

Authors:  E M Reiman; R J Caselli; L S Yun; K Chen; D Bandy; S Minoshima; S N Thibodeau; D Osborne
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

10.  Lack of age-related differences in temporal lobe volume of very healthy adults.

Authors:  C DeCarli; D G Murphy; J A Gillette; J V Haxby; D Teichberg; M B Schapiro; B Horwitz
Journal:  AJNR Am J Neuroradiol       Date:  1994-04       Impact factor: 3.825

View more
  24 in total

1.  Cerebral blood flow is diminished in asymptomatic middle-aged adults with maternal history of Alzheimer's disease.

Authors:  Ozioma C Okonkwo; Guofan Xu; Jennifer M Oh; N Maritza Dowling; Cynthia M Carlsson; Catherine L Gallagher; Alex C Birdsill; Matthew Palotti; Whitney Wharton; Bruce P Hermann; Asenath LaRue; Barbara B Bendlin; Howard A Rowley; Sanjay Asthana; Mark A Sager; Sterling C Johnson
Journal:  Cereb Cortex       Date:  2012-12-12       Impact factor: 5.357

2.  Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.

Authors:  Christine L Tardif; Gabriel A Devenyi; Robert S C Amaral; Sandra Pelleieux; Judes Poirier; Pedro Rosa-Neto; John Breitner; M Mallar Chakravarty
Journal:  Hum Brain Mapp       Date:  2017-11-21       Impact factor: 5.038

3.  Predicting age from cortical structure across the lifespan.

Authors:  Christopher R Madan; Elizabeth A Kensinger
Journal:  Eur J Neurosci       Date:  2018-02-12       Impact factor: 3.386

4.  Participation in cognitively-stimulating activities is associated with brain structure and cognitive function in preclinical Alzheimer's disease.

Authors:  Stephanie A Schultz; Jordan Larson; Jennifer Oh; Rebecca Koscik; Maritza N Dowling; Catherine L Gallagher; Cynthia M Carlsson; Howard A Rowley; Barbara B Bendlin; Sanjay Asthana; Bruce P Hermann; Sterling C Johnson; Mark Sager; Asenath LaRue; Ozioma C Okonkwo
Journal:  Brain Imaging Behav       Date:  2015-12       Impact factor: 3.978

5.  A diffusion model analysis of episodic recognition in preclinical individuals with a family history for Alzheimer's disease: The adult children study.

Authors:  Andrew J Aschenbrenner; David A Balota; Brian A Gordon; Roger Ratcliff; John C Morris
Journal:  Neuropsychology       Date:  2016-02       Impact factor: 3.295

6.  Emergence of mild cognitive impairment in late middle-aged adults in the wisconsin registry for Alzheimer's prevention.

Authors:  Rebecca L Koscik; Asenath La Rue; Erin M Jonaitis; Ozioma C Okonkwo; Sterling C Johnson; Barbara B Bendlin; Bruce P Hermann; Mark A Sager
Journal:  Dement Geriatr Cogn Disord       Date:  2014-02-20       Impact factor: 2.959

7.  Cell death and survival pathways in Alzheimer's disease: an integrative hypothesis testing approach utilizing -omic data sets.

Authors:  Danielle L Brokaw; Ignazio S Piras; Diego Mastroeni; Daniel J Weisenberger; Jennifer Nolz; Elaine Delvaux; Geidy E Serrano; Thomas G Beach; Matthew J Huentelman; Paul D Coleman
Journal:  Neurobiol Aging       Date:  2020-07-03       Impact factor: 4.673

8.  Amyloid burden and neural function in people at risk for Alzheimer's Disease.

Authors:  Sterling C Johnson; Bradley T Christian; Ozioma C Okonkwo; Jennifer M Oh; Sandra Harding; Guofan Xu; Ansel T Hillmer; Dustin W Wooten; Dhanabalan Murali; Todd E Barnhart; Lance T Hall; Annie M Racine; William E Klunk; Chester A Mathis; Barbara B Bendlin; Catherine L Gallagher; Cynthia M Carlsson; Howard A Rowley; Bruce P Hermann; N Maritza Dowling; Sanjay Asthana; Mark A Sager
Journal:  Neurobiol Aging       Date:  2013-10-23       Impact factor: 4.673

9.  Amyloid burden, neuronal function, and cognitive decline in middle-aged adults at risk for Alzheimer's disease.

Authors:  Ozioma C Okonkwo; Jennifer M Oh; Rebecca Koscik; Erin Jonaitis; Caitlin A Cleary; N Maritza Dowling; Barbara B Bendlin; Asenath Larue; Bruce P Hermann; Todd E Barnhart; Dhanabalan Murali; Howard A Rowley; Cynthia M Carlsson; Catherine L Gallagher; Sanjay Asthana; Mark A Sager; Brad T Christian; Sterling C Johnson
Journal:  J Int Neuropsychol Soc       Date:  2014-03-12       Impact factor: 2.892

10.  Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults.

Authors:  Siobhan M Hoscheidt; Erika J Starks; Jennifer M Oh; Henrik Zetterberg; Kaj Blennow; Rachel A Krause; Carey E Gleason; Luigi Puglielli; Craig S Atwood; Cynthia M Carlsson; Sanjay Asthana; Sterling C Johnson; Barbara B Bendlin
Journal:  J Alzheimers Dis       Date:  2016-04-12       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.